EC-T与ET方案在乳腺癌新辅助化疗中的近期疗效观察  

Short-term effects of EC-T and ET regimens on NACT of breast cancer

作　　者：朱明华 常振宇 胡朔枫 郝文德[3] 黄焰 

机构地区：[1]解放军307医院乳腺外科,北京100071 [2]军事医学科学院基础医学研究所 [3]解放军空军总医院普外科

出　　处：《西南国防医药》2016年第11期1256-1259,共4页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的分析化疗方案ET（表柔比星＋多西他赛）与EC-T（表柔比星＋环磷酰胺序贯多西他赛）对新辅助化疗乳腺癌患者的效果及副反应。方法回顾性对比我院119例行新辅助化疗的Ⅱ-Ⅲ期乳腺癌患者的临床病理特征（ET方案68例、EC-T方案51例）,治疗6个周期后观察比较两组治疗效果和副反应差异。结果 EC-T组的病理治疗有效率为80.4%,显著高于ET组的63.2%（P〈0.05）,而两组间保乳率、临床治疗有效率及副反应发生率比较均无统计学差异（P〉0.05）。结论 EC-T方案在不增加副反应的基础上,病理治疗有效率优于ET方案,可使新辅助化疗的乳腺癌患者预后更好。Objective To analyze the effects of chemotherapy regimens ET（epirubicin ＋ taxotere） and EC-T（epirubicin ＋cyclophosphamide taxotere） on the neoadjuvant chemotherapy（NACT） of breast cancer and the side reactions. Methods The clinical pathological characteristics of a total of 119 patients with Ⅱ-Ⅲ stage breast cancer treated with NACT in our hospital（68 with ET regimen and 51 with EC-T） were compared and analyzed in a retrospective manner. The efficacy and side reactions in the two groups after six treatment cycles were observed and compared. Results The pathologically effective rate was 80.4% in EC-T group, which was significantly higher than 63.2% in ET group（P〈0.05）, but there was no significant difference in clinically effective rates, the breast-conserving rates and the common side reactions between the two groups（P〈0.05）. Conclusions EC-T regimen may have higher efficiency of pathological treatment than ET regimen without increasing any side reactions, ensuring better prognosis of patients with breast cancer treated with NACT.

关 键 词：乳腺癌 新辅助化疗 不良反应 疗效 

分 类 号：R737.9[医药卫生—肿瘤]